Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Oncorus
Deal Size : $7.7 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement with Gaeta Therapeutics, Oncorus will advance ONCR-177 as a potential new therapeutic option for cancer patients, including in combination with pembrolizumab and locally delivered Interleukin-12 (IL-12) via oncolytic viral e...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $0.2 million
November 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Oncorus
Deal Size : $7.7 million
Deal Type : Licensing Agreement